Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia—Implications for Vaccine Design

RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine

(2017) Pierre-Louis Hervé et al.   Nanomedicine-Nanotechnology Biology and Medicine

Assessment of Cytokine and Chemokine Signatures as Potential Biomarkers of Childhood Community-acquired Pneumonia Severity

(2017) Shanie Saghafian-Hedengren et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice

(2017) Pablo F. Céspedes et al.   VACCINE

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults

(2016) M. Pamela Griffin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Immunogenicity of an adeno-vector vaccine expressing the F protein of a respiratory syncytial virus manufactured from serum-free suspension culture

(2016) Hsiao-Yun Shao et al.   ANTIVIRAL RESEARCH

Respiratory syncytial virus and influenza are the key viral pathogens in children

(2016) Uzma Bashir et al.   ARCHIVES OF VIROLOGY

Comparison of the frequency of bacterial and viral infections among children with community-acquired pneumonia hospitalized across distinct severity categories: a prospective cross-sectional study

(2016) Amanda C. Nascimento-Carvalho et al.   BMC Pediatrics

Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein

(2016) Velasco Cimica et al.   Clinical and Vaccine Immunology

Non-invasive epicutaneous vaccine against Respiratory Syncytial Virus: Preclinical proof of concept

(2016) Pierre-Louis Hervé et al.   JOURNAL OF CONTROLLED RELEASE

A Recombinant G Protein Plus Cyclosporine A–Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease

(2016) Chaofan Li et al.   JOURNAL OF IMMUNOLOGY

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

(2016) Joanne M. Langley et al.   JOURNAL OF INFECTIOUS DISEASES

Structure and functional dynamics characterization of the ion channel of the human respiratory syncytial virus (hRSV) small hydrophobic protein (SH) transmembrane domain by combining molecular dynamics with excited normal modes

(2016) Gabriela C. Araujo et al.   JOURNAL OF MOLECULAR MODELING

The Density Code for the Development of a Vaccine?

(2016) Wei Cheng   JOURNAL OF PHARMACEUTICAL SCIENCES

Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses

(2016) Concepción Palomo et al.   JOURNAL OF VIROLOGY

Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector

(2016) Bo Liang et al.   JOURNAL OF VIROLOGY

Respiratory Viruses: Influenza, RSV, and Adenovirus in Kidney Transplantation

(2016) Dana J. Hawkinson et al.   SEMINARS IN NEPHROLOGY

Maternal immunization with respiratory syncytial virus fusion protein formulated with a novel combination adjuvant provides protection from RSV in newborn lambs

(2016) R. Garg et al.   VACCINE

Baculovirus vectors expressing F proteins in combination with virus-induced signaling adaptor (VISA) molecules confer protection against respiratory syncytial virus infection

(2016) Yuan Zhang et al.   VACCINE

Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease

(2016) Hye Suk Hwang et al.   VIROLOGY

A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation

(2016) Christopher C. Stobart et al.   Nature Communications

A Phase I Randomized, Observer-Blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of Two Intramuscular Doses of DPX-RSV(A), a Respiratory Syncytial Virus (RSV) Vaccine Containing RSV SH Antigen and a Novel Adjuvant DepoVax, or SH Antigen Co-administered With Aluminum Hydroxide, or Placebo to Healthy Adults ≥50–64 Years of Age

(2016) Joanne Langley et al.   Open Forum Infectious Diseases

Natural helper cells contribute to pulmonary eosinophilia by producing IL-13 via IL-33/ST2 pathway in a murine model of respiratory syncytial virus infection

(2015) Jing Liu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age

(2015) Gregory M. Glenn et al.   JOURNAL OF INFECTIOUS DISEASES

A Druggable Pocket at the Nucleocapsid/Phosphoprotein Interaction Site of Human Respiratory Syncytial Virus

(2015) Mohamed Ouizougun-Oubari et al.   JOURNAL OF VIROLOGY

Community-Acquired Pneumonia Requiring Hospitalization among U.S. Children

(2015) Seema Jain et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-33 Receptor (ST2) Signalling is Important for Regulation of Th2-Mediated Airway Inflammation in a Murine Model of Acute Respiratory Syncytial Virus Infection

(2015) S. Zeng et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Chimpanzee adenovirus– and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults

(2015) Christopher A. Green et al.   Science Translational Medicine

Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections

(2015) Geraldine Taylor et al.   Science Translational Medicine

A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children

(2015) Ruth A. Karron et al.   Science Translational Medicine

Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats

(2015) Myra N. Widjojoatmodjo et al.   VACCINE

Maternal transfer of RSV immunity in cotton rats vaccinated during pregnancy

(2015) Jorge C.G. Blanco et al.   VACCINE

A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism

(2015) Anders Krarup et al.   Nature Communications

Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults

(2015) C A Green et al.   BMJ Open

CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner

(2015) Kwang-Il Jeong et al.   PLoS One

Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention

(2015) Jinghan Jenny Chen et al.   PLoS One

Effects of Anti-G and Anti-F Antibodies on Airway Function after Respiratory Syncytial Virus Infection

(2014) Junyan Han et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis

(2014) Hye Suk Hwang et al.   ANTIVIRAL RESEARCH

Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein

(2014) B. Schepens et al.   EMBO Molecular Medicine

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation

(2014) D Wang et al.   HEALTH TECHNOLOGY ASSESSMENT

Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis

(2014) Raymond J Pickles et al.   JOURNAL OF PATHOLOGY

Chimeric Bovine/Human Parainfluenza Virus Type 3 Expressing Respiratory Syncytial Virus (RSV) F Glycoprotein: Effect of Insert Position on Expression, Replication, Immunogenicity, Stability, and Protection against RSV Infection

(2014) B. Liang et al.   JOURNAL OF VIROLOGY

Novel Vaccine Regimen Elicits Strong Airway Immune Responses and Control of Respiratory Syncytial Virus in Nonhuman Primates

(2014) T. Grunwald et al.   JOURNAL OF VIROLOGY

Modification of the Respiratory Syncytial Virus F Protein in Virus-Like Particles Impacts Generation of B Cell Memory

(2014) M. R. Schmidt et al.   JOURNAL OF VIROLOGY

Development of an Adenovirus-Based Respiratory Syncytial Virus Vaccine: Preclinical Evaluation of Efficacy, Immunogenicity, and Enhanced Disease in a Cotton Rat Model

(2014) E. Kim et al.   JOURNAL OF VIROLOGY

Surface expression of the hRSV nucleoprotein impairs immunological synapse formation with T cells

(2014) P. F. Cespedes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model

(2014) Bart G. Jones et al.   VACCINE

A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5)

(2014) Shannon I. Phan et al.   VACCINE

A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children

(2014) Christopher S Ambrose et al.   Human Vaccines & Immunotherapeutics

A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

(2013) Gabriel J. Robbie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Immune Vulnerability of Infants to Tuberculosis

(2013) Koen Vanden Driessche et al.   Clinical & Developmental Immunology

Regulatory T Cells Prevent Th2 Immune Responses and Pulmonary Eosinophilia during Respiratory Syncytial Virus Infection in Mice

(2013) L. R. Durant et al.   JOURNAL OF VIROLOGY

Motavizumab Treatment of Infants Hospitalized With Respiratory Syncytial Virus Infection Does Not Decrease Viral Load or Severity of Illness

(2013) Octavio Ramilo et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles

(2013) Alan Rigter et al.   PLoS One

Local IL-17A Potentiates Early Neutrophil Recruitment to the Respiratory Tract during Severe RSV Infection

(2013) Arie Jan Stoppelenburg et al.   PLoS One

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

(2013) J. S. McLellan et al.   SCIENCE

RSV Fusion: Time for a New Model

(2013) Peter Mastrangelo et al.   Viruses-Basel

The Definition of Pneumonia, the Assessment of Severity, and Clinical Standardization in the Pneumonia Etiology Research for Child Health Study

(2012) J. Anthony G. Scott et al.   CLINICAL INFECTIOUS DISEASES

Role of human TLR4 in respiratory syncytial virus-induced NF-κB activation, viral entry and replication

(2012) Nico Marr et al.   Innate Immunity

Thymic stromal lymphopoietin is induced by respiratory syncytial virus–infected airway epithelial cells and promotes a type 2 response to infection

(2012) Hai-Chon Lee et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Specific increase in local IL-17 production during recovery from primary RSV bronchiolitis

(2012) Tina E. Faber et al.   JOURNAL OF MEDICAL VIROLOGY

Human Respiratory Syncytial Virus Nucleoprotein and Inclusion Bodies Antagonize the Innate Immune Response Mediated by MDA5 and MAVS

(2012) A. W. Lifland et al.   JOURNAL OF VIROLOGY

Respiratory Syncytial Virus Modified by Deletions of the NS2 Gene and Amino Acid S1313 of the L Polymerase Protein Is a Temperature-Sensitive, Live-Attenuated Vaccine Candidate That Is Phenotypically Stable at Physiological Temperature

(2012) C. Luongo et al.   JOURNAL OF VIROLOGY

The Interactome of the Human Respiratory Syncytial Virus NS1 Protein Highlights Multiple Effects on Host Cell Biology

(2012) W. Wu et al.   JOURNAL OF VIROLOGY

TLR2/MyD88/NF-κB Pathway, Reactive Oxygen Species, Potassium Efflux Activates NLRP3/ASC Inflammasome during Respiratory Syncytial Virus Infection

(2012) Jesus Segovia et al.   PLoS One

Human respiratory syncytial virus viroporin SH: a viral recognition pathway used by the host to signal inflammasome activation

(2012) Kathy Triantafilou et al.   THORAX

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine

(2012) Gregory M. Glenn et al.   VACCINE

Pattern recognition receptors for respiratory syncytial virus infection and design of vaccines

(2012) Ruihong Zeng et al.   VIRUS RESEARCH

Baculovirus-based Vaccine Displaying Respiratory Syncytial Virus Glycoprotein Induces Protective Immunity against RSV Infection without Vaccine-Enhanced Disease

(2012) Sol Kim et al.   Immune Network

Identification of nucleolin as a cellular receptor for human respiratory syncytial virus

(2011) Farnoosh Tayyari et al.   NATURE MEDICINE

Phase 1 Study of the Safety and Immunogenicity of a Live, Attenuated Respiratory Syncytial Virus and Parainfluenza Virus Type 3 Vaccine in Seronegative Children

(2011) David I. Bernstein et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A Novel Inactivated Intranasal Respiratory Syncytial Virus Vaccine Promotes Viral Clearance without Th2 Associated Vaccine-Enhanced Disease

(2011) Dennis M. Lindell et al.   PLoS One

Local innate and adaptive immune responses regulate inflammatory cell influx into the lungs after vaccination with formalin inactivated RSV

(2011) Debby Kruijsen et al.   VACCINE

Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years

(2011) Peter L. Collins et al.   VIRUS RESEARCH

Altered cardiac rhythm in infants with bronchiolitis and respiratory syncytial virus infection

(2010) Susanna Esposito et al.   BMC INFECTIOUS DISEASES

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season

(2010) Pilar Fernández et al.   BMC Pediatrics

TSLP from RSV-stimulated rat airway epithelial cells activates myeloid dendritic cells

(2010) Jianou Qiao et al.   IMMUNOLOGY AND CELL BIOLOGY

Efficient Lung Recruitment of Respiratory Syncytial Virus-Specific Th1 Cells Induced by Recombinant Bacillus Calmette-Guerin Promotes Virus Clearance and Protects from Infection

(2010) K. M. Cautivo et al.   JOURNAL OF IMMUNOLOGY

CD25+ Natural Regulatory T Cells Are Critical in Limiting Innate and Adaptive Immunity and Resolving Disease following Respiratory Syncytial Virus Infection

(2010) D. C. P. Lee et al.   JOURNAL OF VIROLOGY

Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion

(2010) K. Huang et al.   JOURNAL OF VIROLOGY

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

(2010) Harish Nair et al.   LANCET

A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats

(2010) Myra N Widjojoatmodjo et al.   Virology Journal

Impairment of T Cell Immunity by the Respiratory Syncytial Virus: Targeting Virulence Mechanisms for Therapy and Prophylaxis

(2009) P. Gonzalez et al.   CURRENT MEDICINAL CHEMISTRY

Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice

(2009) Lia M. Haynes et al.   JOURNAL OF INFECTIOUS DISEASES

Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice

(2009) W. Zhang et al.   JOURNAL OF VIROLOGY

SAFETY AND ANTIVIRAL ACTIVITY OF MOTAVIZUMAB, A RESPIRATORY SYNCYTIAL VIRUS (RSV)–SPECIFIC HUMANIZED MONOCLONAL ANTIBODY, WHEN ADMINISTERED TO RSV-INFECTED CHILDREN

(2009) Rosanna Lagos et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial

(2009) X. Carbonell-Estrany et al.   PEDIATRICS

Crystal Structure of a Nucleocapsid-Like Nucleoprotein-RNA Complex of Respiratory Syncytial Virus

(2009) R. G. Tawar et al.   SCIENCE

Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV

(2009) Bart Jones et al.   VACCINE

Infection and maturation of monocyte-derived human dendritic cells by human respiratory syncytial virus, human metapneumovirus, and human parainfluenza virus type 3

(2009) Cyril Le Nouën et al.   VIROLOGY

Multiple simultaneous viral infections in infants with acute respiratory tract infections in Spain

(2008) Cristina Calvo et al.   JOURNAL OF CLINICAL VIROLOGY

Nonstructural Proteins 1 and 2 of Respiratory Syncytial Virus Suppress Maturation of Human Dendritic Cells

(2008) S. Munir et al.   JOURNAL OF VIROLOGY

The Role of T Cells in the Enhancement of Respiratory Syncytial Virus Infection Severity during Adult Reinfection of Neonatally Sensitized Mice

(2008) J. S. Tregoning et al.   JOURNAL OF VIROLOGY

Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG

(2008) S. M. Bueno et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells

(2008) P. A. Gonzalez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhancement of Mucosal and Cellular Immune Response in Mice by Vaccination with Respiratory Syncytial Virus DNA Encapsulated with Transfersome

(2008) Jin Xu et al.   VIRAL IMMUNOLOGY